From the clinical studies of the antibody-based agents (i.e., cetuximab-800CW, panitumumab-IRDye800) targeting EGFR in head and neck cancers, a major focus has been on margin assessment in closed-field imaging systems on the back-table or during the pathological processing postoperatively. Here, EGFR is linked to head and neck cancer.